ChromaDex (CDXC) vs. Momenta Pharmaceuticals (MNTA) Financial Comparison
ChromaDex (NASDAQ: CDXC) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.
Volatility and Risk
ChromaDex has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.
6.8% of ChromaDex shares are owned by institutional investors. Comparatively, 93.4% of Momenta Pharmaceuticals shares are owned by institutional investors. 11.6% of ChromaDex shares are owned by company insiders. Comparatively, 4.4% of Momenta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current ratings and recommmendations for ChromaDex and Momenta Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ChromaDex presently has a consensus target price of $7.00, suggesting a potential upside of 11.82%. Momenta Pharmaceuticals has a consensus target price of $14.44, suggesting a potential upside of 12.41%. Given Momenta Pharmaceuticals’ higher possible upside, analysts plainly believe Momenta Pharmaceuticals is more favorable than ChromaDex.
Valuation & Earnings
This table compares ChromaDex and Momenta Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ChromaDex||$26.81 million||12.57||-$2.92 million||($0.14)||-44.71|
|Momenta Pharmaceuticals||$109.62 million||8.95||-$21.00 million||($0.80)||-16.06|
ChromaDex has higher earnings, but lower revenue than Momenta Pharmaceuticals. ChromaDex is trading at a lower price-to-earnings ratio than Momenta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares ChromaDex and Momenta Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ChromaDex beats Momenta Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
ChromaDex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company’s Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company’s programs include M254, M281 (Anti-FcRn candidate) and M230.
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.